Premium
Thioamide derivative‐induced cytotoxic effect in human liver carcinoma (HepG2) cells
Author(s) -
Young Jarrod,
Yedjou Clement,
Cameron Joseph A.,
Tchounwou Paul
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.1056.5
Subject(s) - thioamide , cytotoxic t cell , medicine , cytotoxicity , drug , pharmacology , in vitro , chemistry , biochemistry , stereochemistry
Thioamide is an antithyroid drug that has been shown to cross the placental barrier. Use of antithyroid medications in pregnancy may result in fetal hypothyroidism, goiter, and cretinism. The literature review indicated that about 10% of patients taking thioamide drug have skin eruptions, maculespapules, urticaria, dermatitis, fever, and arthralgia. However, the precise mechanisms involved in thioamide toxicity are not well elucidated. In the present study, we use human liver carcinoma (HepG2) cells as a test model to evaluate the cytotoxicity of three thioamide derivatives. To achieve this goal, cell survival was determined by the means of MTT (3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐ diphenyltetrazolium bromide, a tetrazole) assay. Human liver carcinoma (HepG2) cells were treated with different doses of thioamide derivative for 48 hours. Results from MTT assay indicate that thioamide derivative gradually reduce the viability of HepG2 cells in a dose‐dependent manner, showing LD50 value of about 13.58, 32, and 38μM, upon 48 h of exposure, respectively. Based on this in vitro, our thioamide derivative appears to be highly cytotoxic to HepG2 cells. This research was supported in part by NIH‐NIGMS Grant R 25 GM 50117, and in part by a grant from the National Institutes of Health, Grant No. 2G12RR013459‐11, through the RCMI‐Center for Environmental Health at Jackson State University.